Newly designed drugs that bind to KRAS G12C whether it is in its active or inactive form block cancer signaling faster than older drugs that only bind the inactive form, but after several hours, both types of drugs suppress the cancer signal to the same extent.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether dual-state KRAS G12C inhibitors consistently improve progression-free survival or overall survival compared to inactive-state inhibitors across multiple randomized clinical trials in patients with KRAS G12C-mutant cancers.
A systematic review and meta-analysis of all completed and ongoing phase III randomized controlled trials comparing dual-state KRAS G12C inhibitors (e.g., compound 8) versus inactive-state inhibitors (e.g., sotorasib or adagrasib) in adults with advanced KRAS G12C-mutant non-small cell lung cancer or pancreatic cancer, with primary endpoints of overall survival and progression-free survival, stratified by prior therapy and tumor burden.
Whether dual-state KRAS G12C inhibitors improve clinical outcomes such as tumor response rate or survival compared to inactive-state inhibitors in patients with KRAS G12C-mutant cancers.
A multicenter, double-blind, randomized phase III trial of 600 adults with previously treated KRAS G12C-mutant non-small cell lung cancer, randomized 1:1 to receive oral compound 8 (150 mg daily) or divarasib (120 mg daily) for up to 2 years, with primary endpoint of progression-free survival by RECIST 1.1, secondary endpoints including overall survival, objective response rate, and time to symptomatic progression.
Whether patients treated with dual-state KRAS G12C inhibitors have longer duration of response or lower rates of acquired resistance compared to those treated with inactive-state inhibitors in real-world clinical settings.
A prospective multicenter cohort study of 500 patients with KRAS G12C-mutant cancers treated with either dual-state or inactive-state inhibitors, tracking tumor response, resistance mechanisms via serial liquid biopsy, and survival over 3 years, adjusting for performance status, prior therapies, and co-mutations.
Whether resistance to dual-state KRAS G12C inhibitors is associated with specific genomic alterations (e.g., RTK amplifications, NRAS mutations) compared to resistance to inactive-state inhibitors.
A case-control study comparing 100 patients with acquired resistance to dual-state KRAS G12C inhibitors to 100 matched patients with resistance to inactive-state inhibitors, analyzing tumor and plasma DNA for mutations in KRAS, NRAS, HRAS, EGFR, MET, and other RTKs, and measuring GTP-bound RAS isoforms via pull-down assays.
The prevalence of GTP-bound KRAS G12C in tumor samples from patients treated with dual-state versus inactive-state inhibitors at a single time point.
A cross-sectional analysis of tumor biopsies from 200 patients with KRAS G12C-mutant cancers who received either dual-state or inactive-state inhibitors, measuring GTP-bound KRAS levels via active RAS pull-down assays and correlating with prior treatment duration and response status.